Work

Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023–2024

Year: 2025

Type: review

Abstract: Antibodies against PD-1 (PD1i), such as cemiplimab and pembrolizumab, have demonstrated significant efficacy in advanced, unresectable cutaneous squamous cell carcinoma (cSCC). These agents elicit durable responses in approximately 45% of patients, contributing to improved aesthetic, functional, and survival outcomes in a subset of individuals with advanced cSCC. This review highlights recent and ongoing research investigating the safety and efficacy of immune checkpoint inhibitors for cSCC in the curative intent perioperative settings, advanced/metastatic setting, and within the immunocompromised patient populations.

Source: Cancer

DOI: 10.1002/cncr.35920

Authors: Mateus Trinconi Cunha, Neil Wallace, Sandro Porceddu, Renata Ferrarotto

Institutions: The University of Texas MD Anderson Cancer Center, Peter MacCallum Cancer Centre, The University of Melbourne

Language: English

Topic: Nonmelanoma Skin Cancer Studies

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,790